Cryoport (CYRX) Misses Q2 EPS by 19c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cryoport Reports Second Quarter 2023 Financial Results
August 9, 2023 4:05 PM EDTSecond quarter revenue of $57 million, in line with previously announced preliminary results Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of 42 new trials added year-over-yearStrong balance sheet with over $500 million in cash and short-term investments
NASHVILLE, Tenn., Aug. 9, 2023 /PRNewswire/ --Â Cryoport, Inc. (NASDAQ: CYRX)... More
